Business Wire

  1. First Cancer Patient Receives Dose Of Super-Enhancer Inhibitor GZ17-6.02, An Advanced Cancer Drug From Genzada Pharmaceuticals, At HonorHealth Research Institute

    Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Life Sciences Limited, announced recently that the first patient enrolled in its Phase 1 clinical trial for the oral therapeutic GZ17-6.02 received the first dose this week at HonorHealth Research Institute in Scottsdale, Ariz

  2. Industry Consortium Launched To Qualify Biomarkers For Schizophrenia Drug Development

    The ERP Biomarker Qualification Consortium was launched today by pharmaceutical industry members with the goal of qualifying event-related potential (ERP) biomarkers to aid the development of new investigational therapies for people with schizophrenia in accordance with FDA guidelines

  3. Ono Pharmaceutical And twoXAR Announce Drug Discovery Research Collaboration

    Ono Pharmaceutical Co., Ltd., a Japanese pharmaceutical research and development company, and twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, announced recently that the companies have signed a drug discovery research collaboration to jointly discover and develop novel, efficacious treatments to address unmet medical needs in a specific neurological disease

  4. Iktos Announces Collaboration With Merck KGaA, Darmstadt, Germany, For Use Of Iktos AI Technology Across Three Drug Discovery Projects

    Iktos, a company specialized in Artificial Intelligence for new drug design, recently announced a collaboration agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, where Iktos generative modelling artificial intelligence (AI) technology will be used to facilitate the rapid and cost-effective discovery and design of promising new compounds for Merck KGaA, Darmstadt, Germany

  5. HitGen And SPARC Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration

    HitGen Ltd. and Sun Pharma Advanced Research Company Ltd. (SPARC) recently announced a research collaboration to identify novel small molecule leads for targets of interest. Under this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads for SPARC

  6. Genentech Submits Supplemental New Drug Application To FDA For Venclexta Plus Gazyva For Previously Untreated Chronic Lymphocytic Leukemia With Co-Existing Medical Conditions

    Genentech, a member of the Roche Group, recently announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) for Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) in people with previously untreated chronic lymphocytic leukemia (CLL) and co-existing medical conditions

  7. LifeMap Sciences And iCarbonX Research Shenzhen Announce Strategic Collaboration

    LifeMap Sciences (“LifeMap”), a subsidiary of AgeX Therapeutics, Inc., announced recently that it has entered into a collaboration with iCarbonX Research Shenzhen, enabling iCarbonX to leverage LifeMap’s GeneCards Suite platform in product prototype design and scientific research

  8. Mitochon Pharmaceuticals Awarded Orphan Drug Designation

    Mitochon Pharmaceuticals recently announced that it was awarded Orphan Drug Designation by FDA for its mitochondrial targeted compound, MP-101 for treating Huntington’s Disease

  9. Cyrus Biotechnology Announces Release Of Antibody Structure Prediction Software For Biologics Drug Development And Discovery

    Cyrus Biotechnology, Inc., a Seattle-based biotech software company commercializing Rosetta, an advanced protein design platform, announced recently the release of a novel Antibody Structure Prediction Software tool as part of its Cyrus Bench platform

  10. Acceleron Receives FDA Orphan Drug Designation For ACE-083 In Charcot-Marie-Tooth Disease

    Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, recently announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to ACE-083, the Company’s locally-acting “Myostatin+” muscle agent, for the treatment of patients with Charcot-Marie-Tooth disease (CMT)